JAMA (2019) 321(15):14578
Do any of these apply to you
The brand source materials describe the order as in process at that point because medical, clinical, pharmacy, and fulfillment resources are immediately dedicated to reviewing eligibility, processing prescriptions, and coordinating shipment
More recently, long-acting GLP-1 RAs for obesity have been approved: semaglutide (approved in 2021), resulted in an average weight reduction of around 15% 1214 , and tirzepatide (approved in 2023), demonstrating an average weight reduction of approximately 20% 1517
However, arthralgia is a recognised adverse reaction with approved incretin-based therapies, and any joint symptoms during a trial should be reported to the trial team
If experiencing these despite efforts, contact your doctor same day